# Tsumura & Co. (TSMRF)

> Source: Nexqual · https://nexqual.com/TSMRF · data as of 2026-10-23 20:00 UTC · cite as "Nexqual, Tsumura & Co. (TSMRF), nexqual.com/TSMRF" · informational, not investment advice.

**Price:** USD 23.2 (+0.00% on the day) · last close of Oct 23, 2026; US market closed, not a live price. Prev close 23.2 · day 28.15–28.15 · 52w 23.2–28.15 · market cap $1.73B · PNK

## Key facts
- Analysts: None.
- Total return with dividends: 1Y -107.6% vs S&P 500 +13.4%; 5Y -398.4% vs S&P 500 +76.9%.
- Next earnings: 2026-11-09, EPS estimate USD —, revenue estimate $54.4B.

## Analysts
Consensus None.

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-24) | 5Y (from 2021-10-25) |
|---|---|---|
| Total return | -107.6% | -398.4% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | — | — |
| Volatility (annualized) | — | — |
| Max drawdown | -141.6% (Mar 2026→Mar 2026) | -1001.6% (Mar 2022→Sep 2022) |

## Peers (Drug Manufacturers - Specialty & Generic)
SUPN (Supernus Pharmaceuticals, Inc.) USD 40.7 -3.26% · BHC (Bausch Health Companies Inc.) USD 6.44 -0.77% · HCM (HUTCHMED (China) Limited) USD 14.36 +0.56% · AMLX (Amylyx Pharmaceuticals, Inc.) USD 27.2 -4.80% · RGC (Regencell Bioscience Holdings L) USD 7.67 -21.81% · LQDA (Liquidia Corporation) USD 42.65 +7.46%

## More
Full page: https://nexqual.com/TSMRF · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | — | — | — | $54.37B | — |
| Next quarter (ends 2026-12-31) | — | — | — | $58.33B | — |
| Current fiscal year (ends 2027-03-31) | — | — | — | $214.86B | — |
| Next fiscal year (ends 2028-03-31) | — | — | — | $228.12B | — |